Literature DB >> 10997932

In vitro interaction of codeine and diclofenac.

S Ammon1, O von Richter, U Hofmann, K P Thon, M Eichelbaum, G Mikus.   

Abstract

There is very limited knowledge about possible pharmacokinetic interactions between opioid analgesics and nonsteroidal antiinflammatory drugs (NSAIDs), which are commonly used in combination for the treatment of chronic pain. The major metabolic pathway of the weak opioid codeine is glucuronidation to codeine-6-glucuronide. Therefore we investigated the influence of the NSAID diclofenac on the formation of codeine-6-glucuronide in vitro, using human liver tissue homogenate. The formation of codeine-6-glucuronide exhibited single enzyme Michaelis-Menten kinetics with an average V(max) of 93.6 +/- 35.3 pmol/mg/min. A noncompetitive inhibition of codeine-6-glucuronidation by diclofenac was observed with an average K(i) of 7.9 microM. These in vitro findings suggest that a pharmacokinetic interaction occurs in vivo, which has to be confirmed by an interaction study in human subjects. It can be speculated that in case of inhibition of glucuronidation, the amount of codeine available for other pathways especially O-demethylation to morphine is increased, resulting in higher morphine serum levels and therefore higher analgesic efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997932

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers.

Authors:  Susanne Ammon; Claudia Marx; Christoph Behrens; Ute Hofmann; Thomas Mürdter; Ernst-Ulrich Griese; Gerd Mikus
Journal:  BMC Clin Pharmacol       Date:  2002-02-27

2.  A pharmacokinetic evaluation and metabolite identification of the GHB receptor antagonist NCS-382 in mouse informs novel therapeutic strategies for the treatment of GHB intoxication.

Authors:  Garrett R Ainslie; K Michael Gibson; Kara R Vogel
Journal:  Pharmacol Res Perspect       Date:  2016-10-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.